Detalles de la búsqueda
1.
Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma.
ESMO Open;
8(5): 101619, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37625193
2.
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Ann Oncol;
34(9): 734-771, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37343663
3.
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.
Ann Oncol;
34(4): 431-439, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36549587
4.
Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
Surg Oncol;
38: 101572, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33915487
5.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
ESMO Open;
6(3): 100117, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887690
6.
Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence.
Clin Oncol (R Coll Radiol);
32(9): 591-608, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32595101
7.
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Cancer Chemother Pharmacol;
84(6): 1365, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31587095
8.
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Cancer Chemother Pharmacol;
83(6): 1175-1181, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30927036
9.
Biomarker concordance between primary colorectal cancer and its metastases.
EBioMedicine;
40: 363-374, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733075
10.
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).
Clin Transl Oncol;
21(1): 55-63, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30535553
11.
Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
Clin Transl Oncol;
21(7): 950-953, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30506132
12.
A novel, highly efficient ß-glucosidase with a cellulose-binding domain: characterization and properties of native and recombinant proteins.
Biotechnol Biofuels;
10: 256, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29142591
13.
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Endocr Relat Cancer;
22(4): 657-64, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26113608
14.
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
Clin Transl Oncol;
16(12): 1025-34, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25183048
15.
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Br J Cancer;
111(4): 660-6, 2014 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24960402
16.
Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Clin Transl Oncol;
16(3): 243-56, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23749327
17.
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Invest New Drugs;
31(6): 1573-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24077981
18.
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Br J Cancer;
106(11): 1728-34, 2012 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22531637
19.
Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
Br J Cancer;
106(6): 1246, 2012 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22294185
20.
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
Curr Cancer Drug Targets;
12(2): 124-31, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22229245